Format

Send to

Choose Destination
Exp Hematol. 2009 Sep;37(9):1016-21. doi: 10.1016/j.exphem.2009.06.006. Epub 2009 Jun 24.

JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

Author information

1
Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy.

Abstract

OBJECTIVE:

A direct comparison of the incidence and risk factors of major thrombosis in essential thrombocythemia (ET) and polycythemia vera (PV) according to their respective JAK2V617F allele burden is the object of this study.

MATERIALS AND METHODS:

We compared the rate (%/patients/year) of major thrombosis in 867 ET patients (57% JAK2V617F) with that of 415 PV patients (all JAK2V617F) and examined risk factors.

RESULTS:

Patients with ET wild-type, ET V617F, and PV showed a rate of thrombosis of 1.4%, 2.1%, and 2.7%/patients/year, respectively. The latter was found to progressively increase according to time of diagnosis. Actuarial probability of arterial and venous thrombosis in the first 5 years of diagnosis was roughly similar in the three groups. While in the subsequent periods, the curves of mutated ET patients diverged from wild-type, and after 10 to 15 years the ET-mutated arm approached PV.

CONCLUSION:

These findings support the concept of a continuum between ET JAK2 mutated and PV, not only in reference to the hematological phenotype, but also in terms of vascular events.

PMID:
19559071
PMCID:
PMC2746993
DOI:
10.1016/j.exphem.2009.06.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center